Consequently, these drugs have been recommended in international clinical practice guidelines, such as the NCCN [10] and the ESMO [11] as the first-line treatment of advanced NSCLC with EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.